» Articles » PMID: 33259328

Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository

Abstract

Objective: The APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients. Our primary objective was to determine whether clinically meaningful aPL profiles at baseline remain stable over time. Our secondary objectives were to determine (1) whether baseline characteristics differ between patients with stable and unstable aPL profiles, and (2) predictors of unstable aPL profiles over time.

Methods: A clinically meaningful aPL profile was defined as positive lupus anticoagulant (LAC) test and/or anticardiolipin (aCL)/anti-β glycoprotein-I (anti-β-GPI) IgG/M ≥ 40 U. Stable aPL profile was defined as a clinically meaningful aPL profile in at least two-thirds of follow-up measurements. Generalized linear mixed models with logit link were used for primary objective analysis.

Results: Of 472 patients with clinically meaningful aPL profile at baseline (median follow-up 5.1 yrs), 366/472 (78%) patients had stable aPL profiles over time, 54 (11%) unstable, and 52 (11%) inconclusive. Time did not significantly affect odds of maintaining a clinically meaningful aPL profile at follow-up in univariate ( = 0.906) and multivariable analysis ( = 0.790). Baseline triple aPL positivity decreased (OR 0.25, 95% CI 0.10-0.64, = 0.004) and isolated LAC test positivity increased (OR 3.3, 95% CI 1.53-7.13, = 0.002) the odds of an unstable aPL profile over time.

Conclusion: Approximately 80% of our international cohort patients with clinically meaningful aPL profiles at baseline remain stable at a median follow-up of 5 years; triple aPL-positivity increase the odds of a stable aPL profile. These results will guide future validation studies of stored blood samples through APS ACTION Core Laboratories.

Citing Articles

Antiphospholipid antibody positivity is associated with maturation failure and thrombosis of native arteriovenous fistula: a retrospective study in HD patients.

Taghavi M, Jacobs L, Demulder A, Jabrane A, Mesquita M, Defawe C Clin Kidney J. 2024; 17(11):sfae308.

PMID: 39512379 PMC: 11540859. DOI: 10.1093/ckj/sfae308.


Exploring clinical indicator variations in stroke patients with multiple risk factors: focus on hypertension and inflammatory reactions.

Guo J, Tian M, Li Y, Guo Y, Zhang T, Liu X Eur J Med Res. 2024; 29(1):81.

PMID: 38287458 PMC: 10823715. DOI: 10.1186/s40001-024-01653-6.


Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature.

Taghavi M, Jabrane A, Jacobs L, Mesquita M, Demulder A, Nortier J Antibodies (Basel). 2024; 13(1).

PMID: 38247565 PMC: 10801604. DOI: 10.3390/antib13010001.


Trophoblast Cell Function in the Antiphospholipid Syndrome.

Vrzic Petronijevic S, Vilotic A, Bojic-Trbojevic Z, Kostic S, Petronijevic M, Vicovac L Biomedicines. 2023; 11(10).

PMID: 37893055 PMC: 10604227. DOI: 10.3390/biomedicines11102681.


Novel maternal autoantibodies in autism spectrum disorder: Implications for screening and diagnosis.

Mazon-Cabrera R, Liesenborgs J, Brone B, Vandormael P, Somers V Front Neurosci. 2023; 17:1067833.

PMID: 36816132 PMC: 9932693. DOI: 10.3389/fnins.2023.1067833.


References
1.
Udry S, Latino J, Belizna C, Wingeyer S, Romero D, de Larranaga G . A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome. Immunol Res. 2019; 67(6):478-485. DOI: 10.1007/s12026-019-09110-x. View

2.
Favaloro E, Mohammed S, Curnow J, Pasalic L . Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. Pathology. 2019; 51(3):292-300. DOI: 10.1016/j.pathol.2018.11.008. View

3.
Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide M, Garmendia M, Erdozain J, Villar I . Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus. 2007; 16(10):810-6. DOI: 10.1177/0961203307083316. View

4.
Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

5.
Galli M, Luciani D, Bertolini G, Barbui T . Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2002; 101(5):1827-32. DOI: 10.1182/blood-2002-02-0441. View